Alvaro Lucioni, MD
Urology · Seattle, WANPI 1639344534
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medtronic at 47.3% of the total. 2025 is the largest year on record at $91,658, more than ten times the $2,409 reported in 2019. Among urology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $606.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$70K
- Coloplast$38K
- AbbVie$19K
- Boston Scientific$18K
- Cook Incorporated$1K
- SWAN Valley Medical Incorporated$987
- plus $2K from 12 others
Across 4 payments — averaging $1048.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$49,56433%
- Speaking & faculty fees$66,91845%
- Travel & lodging$23,04316%
- Food & beverage$8,5776%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 148 | $69,985 |
| Coloplast | 37 | $37,798 |
| AbbVie | 21 | $18,608 |
| Boston Scientific | 16 | $17,704 |
| Cook Incorporated | 1 | $1,230 |
| SWAN Valley Medical Incorporated | 4 | $987 |
| EDAP Technomed Inc | 3 | $624 |
| Axonics, Inc. | 3 | $297 |
| Calyxo, Inc. | 1 | $158 |
| Teleflex LLC | 1 | $157 |
| Neotract Inc. | 1 | $147 |
| Procept Biorobotics Corporation | 2 | $119 |
| Cook Medical LLC | 1 | $105 |
| Convatec Inc. | 1 | $104 |
| Sumitomo Pharma America, Inc. | 1 | $34 |
| Urovant Sciences Inc | 1 | $32 |
| Valencia Technologies Corporation | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$39,235
- Luja Coude$35,509
- ALTAVIVA$23,135
- BOTOX$18,090
- GENERAL - THERAPIES$8,832
- Axonics$8,231
- S~Curve$1,230
- GENERAL KIDNEY STONE DISEASE$540
- UroLift$304
- Bulkamid$282
- INTELLIS ADAPTIVESTIM$253
- INTERSTIM ICON$160
- CVAC Aspiration System$158
- TITAN$152
- RESTORELLE$141
- Cook Medical Holmium Laser Fiber$105
- GENTLECATH$104
- AquaBeam Robotic System$102
How this compares
$148,105 in reported general payments places this provider in the 95th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 234 | $181,865 |
| GemtesaVibegron | 143 | $93,197 |
| Mirabegron ErMirabegron | 17 | $11,772 |
| Estradiol | 49 | $5,364 |
| Trospium Chloride ErTrospium Chloride | 23 | $3,387 |
| Tamsulosin Hcl | 272 | $3,170 |
| Methenamine Hippurate | 32 | $2,590 |
| Trospium Chloride | 35 | $2,142 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 32 | $1,427 |
| Silodosin | 28 | $1,412 |
| Tadalafil | 16 | $1,008 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 42 | $978 |
| Finasteride | 103 | $888 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $827 |
| Trimethoprim | 12 | $569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $93,197143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Washington.
Other urology in Seattle
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Thomas WalshSeattle$186K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Vi NguyenSeattle$53K
- Rogerio HuangSeattle$45K
- Cristopher GarlitzSeattle$45K
- Sarah PsutkaSeattle$40K
- Daniel LinSeattle$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.